1. Leukotrienes and Asthma
- Author
-
Rejean Fortin, C. Chan, H. Piechuta, S. S. Pong, D. Denis, DeHaven Rn, Joshua Rokach, Howard E. Morton, Hollis R. Williams, Larry Peterson, Stella Charleson, C. Rouzer, L. Charette, E. Champion, Thomas R. Jones, Robert Zamboni, Joe Metzger, Denis Riendeau, S. L. Hopple, C. S. Mcfarlane, G. Eiermann, Jillian F. Evans, Roger Meurer, Robert N. Young, T. Bach, Richard Frenette, A. Foster, L. Hupe, John L. Humes, Silvi Luell, Douglas K. Miller, E. E. Opas, Serge Leger, C. Leveillé, Y. Guidon, Jacques-Yves Gauthier, Richard A. F. Dixon, Anthony W. Ford-Hutchinson, P. Masson, A. Lord, Yves Girard, Diane Ethier, M. Belley, John W. Gillard, Pierre Hamel, D. E. Mc McIntyre, Christiane Yoakim, M. Barth, and Stephen G. Pacholok
- Subjects
chemistry.chemical_compound ,Chemistry ,In vivo ,medicine ,Biological activity ,Arachidonic acid ,Pharmacology ,medicine.disease ,Antigen challenge ,In vitro ,Anaphylaxis ,Asthma - Abstract
The peptide leukotrienes LTC4, D4 and E4 collectively account for the biological activity known as slow-reacting substance of anaphylaxis (SRS-A). These metabolites of arachidonic acid are thought to play a role in lung pathophysiology. A role in asthma is postulated as a result of their potent bronchoconstrictor activity both in vitro (Dahlen et al. 1980; Drazen et al. 1980; Hanna et al. 1981; Piper et al. 1981; Jones et al. 1982; Peters et al. 1984) and in vivo (Manning et al. 1990; Holroyde et al. 1981; Griffin et al. 1983; Weiss et al. 1982; Barnes et al. 1984). Increased production of leukotrienes has been demonstrated following antigen challenge of the airways of allergic patients in vivo (Creticos et al. 1984; Ishihara et al. 1985; Isono et al. 1985) and in vitro (Dalhen et al. 1983).
- Published
- 1992